Shionogi said on July 6 that it has restored exclusive US rights to its opioid-induced constipation (OIC) treatment Symproic (naldemedine) that the Japanese company previously granted to its US partner Purdue Pharma L.P., under their strategic partnership deal on the…
To read the full story
Related Article
- No Major Impact on Shionogi, Eisai from Purdue’s Bankruptcy Filing
September 18, 2019
- Shionogi Hooks Up with Purdue on Naldemedine Commercialization in US
December 20, 2016
BUSINESS
- Expert Calls for Greater Awareness of LC-FAOD after Dojolvi Debut
June 30, 2026
- Toho Defense Measure Scraped through Shareholder Vote: Report
June 30, 2026
- Enhertu Snags EU Approval in HER2 Positive Solid Tumors
June 30, 2026
- Datroway Grabs Positive CHMP Opinion in 1st-Line TNBC
June 30, 2026
- Tanabe Gets Thai Approval for Diabetes Drug Canalia
June 30, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…





